245 related articles for article (PubMed ID: 24257427)
21. Protection against congenital cytomegalovirus infection and disease in guinea pigs, conferred by a purified recombinant glycoprotein B vaccine.
Schleiss MR; Bourne N; Stroup G; Bravo FJ; Jensen NJ; Bernstein DI
J Infect Dis; 2004 Apr; 189(8):1374-81. PubMed ID: 15073673
[TBL] [Abstract][Full Text] [Related]
22. Enveloped virus-like particle expression of human cytomegalovirus glycoprotein B antigen induces antibodies with potent and broad neutralizing activity.
Kirchmeier M; Fluckiger AC; Soare C; Bozic J; Ontsouka B; Ahmed T; Diress A; Pereira L; Schödel F; Plotkin S; Dalba C; Klatzmann D; Anderson DE
Clin Vaccine Immunol; 2014 Feb; 21(2):174-80. PubMed ID: 24334684
[TBL] [Abstract][Full Text] [Related]
23. The history of vaccination against cytomegalovirus.
Plotkin S
Med Microbiol Immunol; 2015 Jun; 204(3):247-54. PubMed ID: 25791890
[TBL] [Abstract][Full Text] [Related]
24. Multiantigenic Modified Vaccinia Virus Ankara Vaccine Vectors To Elicit Potent Humoral and Cellular Immune Reponses against Human Cytomegalovirus in Mice.
Chiuppesi F; Nguyen J; Park S; Contreras H; Kha M; Meng Z; Kaltcheva T; Iniguez A; Martinez J; La Rosa C; Wussow F; Diamond DJ
J Virol; 2018 Oct; 92(19):. PubMed ID: 30045984
[TBL] [Abstract][Full Text] [Related]
25. Multi-antigenic human cytomegalovirus mRNA vaccines that elicit potent humoral and cell-mediated immunity.
John S; Yuzhakov O; Woods A; Deterling J; Hassett K; Shaw CA; Ciaramella G
Vaccine; 2018 Mar; 36(12):1689-1699. PubMed ID: 29456015
[TBL] [Abstract][Full Text] [Related]
26. Induction of innate immune signatures following polyepitope protein-glycoprotein B-TLR4&9 agonist immunization generates multifunctional CMV-specific cellular and humoral immunity.
Dasari V; Smith C; Schuessler A; Zhong J; Khanna R
Hum Vaccin Immunother; 2014; 10(4):1064-77. PubMed ID: 24463331
[TBL] [Abstract][Full Text] [Related]
27. Update on the current status of cytomegalovirus vaccines.
Sung H; Schleiss MR
Expert Rev Vaccines; 2010 Nov; 9(11):1303-14. PubMed ID: 21087108
[TBL] [Abstract][Full Text] [Related]
28. Intrahost Dynamics of Human Cytomegalovirus Variants Acquired by Seronegative Glycoprotein B Vaccinees.
Nelson CS; Vera Cruz D; Su M; Xie G; Vandergrift N; Pass RF; Forman M; Diener-West M; Koelle K; Arav-Boger R; Permar SR
J Virol; 2019 Mar; 93(5):. PubMed ID: 30518646
[TBL] [Abstract][Full Text] [Related]
29. The cytomegalovirus gB/MF59 vaccine candidate induces antibodies against an antigenic domain controlling cell-to-cell spread.
Gomes AC; Baraniak IA; Lankina A; Moulder Z; Holenya P; Atkinson C; Tang G; Mahungu T; Kern F; Griffiths PD; Reeves MB
Nat Commun; 2023 Feb; 14(1):1041. PubMed ID: 36823200
[TBL] [Abstract][Full Text] [Related]
30. Protection against Congenital CMV Infection Conferred by MVA-Vectored Subunit Vaccines Extends to a Second Pregnancy after Maternal Challenge with a Heterologous, Novel Strain Variant.
Fernández-Alarcón C; Buchholz G; Contreras H; Wussow F; Nguyen J; Diamond DJ; Schleiss MR
Viruses; 2021 Dec; 13(12):. PubMed ID: 34960820
[TBL] [Abstract][Full Text] [Related]
31. Pentameric complex of viral glycoprotein H is the primary target for potent neutralization by a human cytomegalovirus vaccine.
Freed DC; Tang Q; Tang A; Li F; He X; Huang Z; Meng W; Xia L; Finnefrock AC; Durr E; Espeseth AS; Casimiro DR; Zhang N; Shiver JW; Wang D; An Z; Fu TM
Proc Natl Acad Sci U S A; 2013 Dec; 110(51):E4997-5005. PubMed ID: 24297878
[TBL] [Abstract][Full Text] [Related]
32. Recombinant modified vaccinia virus Ankara expressing a soluble form of glycoprotein B causes durable immunity and neutralizing antibodies against multiple strains of human cytomegalovirus.
Wang Z; La Rosa C; Maas R; Ly H; Brewer J; Mekhoubad S; Daftarian P; Longmate J; Britt WJ; Diamond DJ
J Virol; 2004 Apr; 78(8):3965-76. PubMed ID: 15047812
[TBL] [Abstract][Full Text] [Related]
33. Progress on pursuit of human cytomegalovirus vaccines for prevention of congenital infection and disease.
Fu TM; An Z; Wang D
Vaccine; 2014 May; 32(22):2525-33. PubMed ID: 24681264
[TBL] [Abstract][Full Text] [Related]
34. Optimized enzyme-linked immunosorbent assay for detecting cytomegalovirus infections during clinical trials of recombinant vaccines.
Pagnon A; Piras F; Gimenez-Fourage S; Dubayle J; Arnaud-Barbe N; Hessler C; Caillet C
J Clin Virol; 2017 Nov; 96():99-104. PubMed ID: 29035763
[TBL] [Abstract][Full Text] [Related]
35. Comparison of vaccine strategies against congenital CMV infection in the guinea pig model.
Schleiss MR
J Clin Virol; 2008 Mar; 41(3):224-30. PubMed ID: 18060834
[TBL] [Abstract][Full Text] [Related]
36. Recombinant glycoprotein B vaccine formulation with Toll-like receptor 9 agonist and immune-stimulating complex induces specific immunity against multiple strains of cytomegalovirus.
Dasari V; Smith C; Zhong J; Scott G; Rawlinson W; Khanna R
J Gen Virol; 2011 May; 92(Pt 5):1021-1031. PubMed ID: 21307228
[TBL] [Abstract][Full Text] [Related]
37. Neutralization of Diverse Human Cytomegalovirus Strains Conferred by Antibodies Targeting Viral gH/gL/pUL128-131 Pentameric Complex.
Ha S; Li F; Troutman MC; Freed DC; Tang A; Loughney JW; Wang D; Wang IM; Vlasak J; Nickle DC; Rustandi RR; Hamm M; DePhillips PA; Zhang N; McLellan JS; Zhu H; Adler SP; McVoy MA; An Z; Fu TM
J Virol; 2017 Apr; 91(7):. PubMed ID: 28077654
[TBL] [Abstract][Full Text] [Related]
38. Clinical evaluation of safety and immunogenicity of PADRE-cytomegalovirus (CMV) and tetanus-CMV fusion peptide vaccines with or without PF03512676 adjuvant.
La Rosa C; Longmate J; Lacey SF; Kaltcheva T; Sharan R; Marsano D; Kwon P; Drake J; Williams B; Denison S; Broyer S; Couture L; Nakamura R; Dadwal S; Kelsey MI; Krieg AM; Diamond DJ; Zaia JA
J Infect Dis; 2012 Apr; 205(8):1294-304. PubMed ID: 22402037
[TBL] [Abstract][Full Text] [Related]
39. Immunogenicity of a recombinant human cytomegalovirus gB vaccine in seronegative toddlers.
Mitchell DK; Holmes SJ; Burke RL; Duliege AM; Adler SP
Pediatr Infect Dis J; 2002 Feb; 21(2):133-8. PubMed ID: 11840080
[TBL] [Abstract][Full Text] [Related]
40. Vaccine prevention of maternal cytomegalovirus infection.
Pass RF; Zhang C; Evans A; Simpson T; Andrews W; Huang ML; Corey L; Hill J; Davis E; Flanigan C; Cloud G
N Engl J Med; 2009 Mar; 360(12):1191-9. PubMed ID: 19297572
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
